AI brief of an SEC Form 8-K · Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics Q3 net loss narrows to $51.0 million; cash at $1.05 billion
Definium Therapeutics reported a third-quarter 2026 net loss of $51.0 million, down from $67.3 million a year earlier, mainly because of a gain from the change in fair value of its 2022 USD financing warrants and higher interest income. Operating expenses rose to $72.3 million from $45.7 million as research and development and general and administrative spending grew, and the company said its cash position will fund operations into 2030.
Key points
- Net loss was $51.0 million, or $0.37 per basic share, versus $67.3 million, or $0.78 per share, a year earlier.
- Total operating expenses were $72.3 million versus $45.7 million; R&D was $46.1 million and G&A was $26.1 million.
- Cash, cash equivalents and investments were approximately $1.05 billion as of September 30, 2026, which the company expects to fund operations into 2030.
- Positive Phase 3 Voyage results in GAD showed a 5.4-point placebo-adjusted HAM-A improvement, and DT120 ODT received FDA Breakthrough Therapy designation in MDD.
The filing
CompanyDefinium Therapeutics, Inc. (DFTX)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:10 PM ET
Accession number0001193125-26-453595
Written by AI on Nov 9, 2026, 6:16 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.